Literature DB >> 29380167

Scores versus clinical profiles in therapeutic decisions: a positive example from the Italian Medicines Agency (AIFA) decisions in the field of osteoporosis.

Antonio Del Puente1, Antonella Esposito2, Luisa Costa2, Francesco Caso2, Raffaele Scarpa2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29380167     DOI： 10.1007/s10067-018-3995-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  19 in total

Review 1.  Assessment of fracture risk.

Authors:  John A Kanis; Frederik Borgstrom; Chris De Laet; Helena Johansson; Olof Johnell; Bengt Jonsson; Anders Oden; Niklas Zethraeus; Bruce Pfleger; Nikolai Khaltaev
Journal:  Osteoporos Int       Date:  2004-12-23       Impact factor: 4.507

Review 2.  Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?

Authors:  Theodore Pincus; Martin J Bergman; Yusuf Yazici
Journal:  Clin Exp Rheumatol       Date:  2015-10-15       Impact factor: 4.473

3.  Meaning and the Nature of Physicians' Work.

Authors:  David I Rosenthal; Abraham Verghese
Journal:  N Engl J Med       Date:  2016-11-10       Impact factor: 91.245

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference.

Authors:  Karin Bruynesteyn; Désirée van der Heijde; Maarten Boers; Ariane Saudan; Paul Peloso; Harold Paulus; Harry Houben; Bridget Griffiths; John Edmonds; Barry Bresnihan; Annelies Boonen; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2002-04

Review 6.  [OSTEOPOROSIS AND PERSONALIZED MEDICINE].

Authors:  J Y Reginster; A Neuprez; M P Lecart; C Beaudart; F Buckinx; J Slomian; O Bruyère
Journal:  Rev Med Liege       Date:  2015 May-Jun

7.  Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools.

Authors:  Silvano Adami; Francesco Bertoldo; Davide Gatti; Giovanni Minisola; Maurizio Rossini; Luigi Sinigaglia; Massimo Varenna
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

8.  Goal-directed treatment of osteoporosis in Europe.

Authors:  J A Kanis; E McCloskey; J Branco; M-L Brandi; E Dennison; J-P Devogelaer; S Ferrari; J-M Kaufman; S Papapoulos; J-Y Reginster; R Rizzoli
Journal:  Osteoporos Int       Date:  2014-09-09       Impact factor: 4.507

Review 9.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.